Join Alexandra Chambers & oncologist Dr. Craig Earle with CADTH's pan-Canadian Oncology Drug Review (pCODR) as they discuss the opportunities for clinicians to participate in the process and be part of the system, and how clinician input can help to inform cancer drug funding recommendations to enhance patient outcomes for Canadians. 3Sixty Public Affairs' Bill Dempster moderated this interactive webinar that included opportunities for participants to participate in polling and ask questions.

1. The importance of clinician engagement in
the HTA process
Alexandra Chambers & Dr. Craig Earle
CADTH pan-Canadian Oncology Drug Review Program

2. Agenda
• About CADTH’s pan-Canadian Oncology Drug
Review (pCODR) Program
• Overview of the pCODR process
• Clinician participation in pCODR program
• Value of Engagement: a clinician’s perspective

3. Polling Question #1
• Participants attending this session
– Please select:
a) Patient Representative
b) Clinician
c) Industry Member
d) Consultant
e) Government/HTA organization
f) Other

4. CADTH’s pCODR Program
• Assess cancer drugs and make recommendations
to ministries of health and provincial cancer
agencies, to guide their drug funding decisions
• Designed to bring consistency and clarity to
assessment of cancer drugs by looking at clinical
evidence, cost-effectiveness and patient
perspectives
• Committed to transparency and the need to be
accountable to patients and public, and
responsive to industry

5. Polling Question #2
• How much do you know about the public
drug funding and approval process in
Canada?
– Please select:
a) Good knowledge
b) Fair, a refresher would be helpful
c) This is new information

6. 6
Drug Access—Who Does What
Health Canada
Regulator
(Effect &
safety)
CDR
(CADTH)
pCODR
(CADTH)
Quebec
(INESSS)
HTA
(Assess
value)
Pan Canadian Pharmaceutical
Alliance (pCPA)
Price
negotiator
F/P/T Ministries of Health and
Cancer Agencies
Decision
maker/
funder

7. Clinician Engagement in pCODR
• Each drug review includes a Clinical Guidance
Panel of 3-5 expert clinicians to provide
clinical interpretation and context of drug
under review
• pCODR Expert Review Committee (pERC)
includes several clinician members in addition
to patient members, health economists, and
pharmacists
• In February 2016, Registered Clinician
input/feedback was introduced

8. pCODR Review Process
Provincial Advisory
Group
Submitter
Patient Advocacy
Group
Registered Clinician
Review Team
Registered Clinician
Provincial Advisory
Group
Patient Advocacy
Group
pCODR Expert
Review Committee
Submitter
INPUT
SUBMISSION
REVIEW
DELIBERATIONS
FEEDBACK
Initial
Recommendation
Final
Recommendation
Review Team:
• Clinical Guidance Panel
• Economic Guidance Panel
• Health Research Methodologist

9. Why include registered clinician input?
Objectives:
1. Collaboration and Representation
– Expands participation to involve oncologists in the
community
– Enables cancer specialists to provide input on value
of a particular drug and its place in therapy
2. Value-added information
– Provides insight into regional and local issues from a
practice setting perspective for Review Team and
pERC

10. How can clinicians participate?
• Must register with pCODR – one time
registration process
• Eligibility:
– you are an actively practising oncologist
– you are a member of a provincial cancer agency or similar
body or a national cancer organization and
• Note: If a clinician is selected as a pERC member or for the
Clinical Guidance Panel to review a specific drug product – that
clinician will not be eligible to provide input or feedback on that
specific review

11. Polling Question #3
• Have you registered to provide input on a
pCODR drug review?
– Please select:
a) Yes
b) No

12. How is clinician input submitted?
• Email notifications are sent 1 month in advance
of drug submission to pCODR
• Deadline for input is 10 business days after the
submission is received
• Registered clinician input template to complete
• Information received from registered clinicians is
summarized and incorporated in pCODR reports
Note: CADTH has discretion to remove any information that may be out of
scope of the review

13. More on submitting clinician input…
• Input can be submitted by an individual oncologist or
• One joint input can be submitted by a group of oncologists:
– only one input form is submitted but all contributing oncologists are
identified
– lead oncologist to indicate input is joint effort
– all oncologists in the group must register
– all must provide own declaration of conflict of interests
• Declaration of conflict of interests must be provided with each
input submitted
• Clinician input and feedback, including COI will be publicly
posted on CADTH website – applies to all participants in
pCODR process

14. Polling Question #4
• For those who have registered, have you
provided input on a pCODR drug review?
– Please select:
a) Yes
b) No

15. Polling Question #5
• If you have registered, please indicate why you
have not yet provided input
– Please select:
a) A relevant drug has not been reviewed
b) A relevant drug was reviewed, but I did not have enough
experience prescribing it to make a meaningful
contribution
c) A relevant drug was reviewed, but I did not have time to
submit input
d) A relevant drug was reviewed, but I found the process for
completing the template to be too complicated
e) I didn’t know about the registered clinician process
f) None of the above – other reasons

16. How can clinicians respond to a pERC
recommendation?
• Through registered clinician feedback
• If a registered clinician provides input, he/she
can also provide feedback on the initial pERC
recommendation
• Template for feedback
• 10 business days to provide feedback after
initial pERC recommendation is posted on
CADTH website

17. pCODR Expert Review Committee
Clinician input presented,
used in deliberations &
reflected in
recommendations
How is clinician input used?
CADTH Review Team
Clinician input used to
inform protocol &
reports
Public Drug Plans
Shared with
participating
jurisdictions and shared
at www.cadth.ca/pcodr

18. Why should clinicians engage in
pCODR?
• Clinician participation in pCODR process
– contributes to shaping the availability of cancer drugs
based on clinical evidence
– shared experiences provides a way for clinicians to be
part of the system to enhance patient outcomes for
Canadians
• For more information about pCODR’s clinician
engagement process, please see:
https://www.cadth.ca/pcodr/clinician-input-and-
feedback

19. Polling Question #6
• Did you find this session helpful in
understanding about the clinician
engagement process through pCODR?
– Please select:
a) Yes
b) No

20. Thank You & Questions

21. @CADTH_ACMTS linkedin.com/company/cadth
slideshare.net/CADTH-ACMTS youtube.com/CADTHACMTS
cadth.ca/photoblog requests@cadth.ca
Connect With Us

22. Canadian Cancer Survivor Network
Contact Info
Canadian Cancer Survivor Network
1750 Courtwood Crescent, Suite 210
Ottawa, ON K2C 2B5
Telephone / Téléphone : 613-898-1871
E-mail jmanthorne@survivornet.ca or mforrest@survivornet.ca
Web site www.survivornet.ca
Instagram: @survivornet_ca
Twitter: @survivornetca
Facebook: www.facebook.com/CanadianSurvivorNet
Pinterest: http://pinterest.com/survivornetwork/